Last updated: February 27, 2026
What is the drug identified by NDC 42292-0017?
NDC 42292-0017 corresponds to Zepzelca (Lurbinectedin), a cancer therapy approved by the U.S. Food and Drug Administration (FDA) in June 2020. It is indicated for small cell lung cancer (SCLC) with metastatic disease, particularly after failure of platinum-based chemotherapy.
Current Market Landscape for Zepzelca
Market Approval and Patient Population
- FDA approval date: June 2020.
- Indication: Treatment of metastatic small cell lung cancer, primarily in relapsed settings.
- Estimated eligible patients in the U.S.: Approximately 30,000 annually, considering incidence and relapse rates (SEER data).
Competitors and Market Share
- Main competitors include topotecan derivatives, third-line therapies like topotecan, and emerging immunotherapies.
- Zepzelca's market share: Estimated at approximately 10-15% among third-line SCLC therapies, limited by high-cost and specific indications.
Pricing and Reimbursement Landscape
- List price (U.S.): Approximately $11,620 per infusion (per 40 mg vial).
- Dosing regimen: 3.2 mg/m² given as an infusion every three weeks.
- Reimbursement trend: Covered under commercial, Medicaid, and Medicare plans. Reimbursement rates vary but generally align with list prices, subject to discounts and patient assistance programs.
Pricing Trends and Potential
Price Trends (2020-2023)
- Initial launch price: $11,620 per dose.
- Adjustments: Slight discounts and patient assistance programs to improve accessibility.
- Negotiated prices (Medicaid, commercial insurers): Estimated between 20-30% below list price.
- Price elasticity: Limited flexibility due to specialty niche and limited competition.
Future Price Projections
| Year |
Expected Price Range (per dose) |
Comments |
| 2023 |
$10,000 – $11,620 |
Current market stability; no large price cuts |
| 2024 |
$9,500 – $11,000 |
Possible moderate discounts, especially via PBMs |
| 2025 |
$9,000 – $10,500 |
Price compression expected with increased competition or biosimilar entry |
Market Growth Projections
- Compound annual growth rate (CAGR) in the SCLC niche: Approx. 3-5% over the next five years.
- Drivers: Increasing incidence of lung cancer; expansion of third-line treatment options; new clinical data supporting combination use.
- Constraints: Pricing pressures, patent exclusivity periods ending, and competition from emerging therapies.
Regulatory and Policy Impact
- Patent protections extend until 2028.
- Expected biosimilar or generic entry: Not applicable, as Zepzelca is an innovative compound with no current biosimilar options.
- Price control measures: Discussions around drug pricing transparency and cap policies may influence future pricing strategies.
Key Market Risks
- Competition from newer agents, including immunotherapies.
- Delays or rejections in expanding indications.
- Reimbursement restrictions or coverage reduction due to cost concerns.
Conclusion
Zepzelca’s market is relatively niche with stable pricing, poised for modest growth driven by the overall increase in lung cancer cases and treatment advancements. The current list price remains high, with some concessions through payers. Future pricing will likely face downward pressure but will depend on competitive landscape developments and regulatory policies.
Key Takeaways
- NDC 42292-0017 (Zepzelca) is a late-line therapy for relapsed small cell lung cancer, with stable high pricing.
- The drug’s U.S. list price is approximately $11,620 per infusion; real-world prices may vary downward.
- Market growth is moderate, driven by increased lung cancer incidence and treatment algorithm evolution.
- Price projections suggest slight reductions over the next two years, contingent on competitive pressures and policy shifts.
- The absence of biosimilars or generics maintains the current pricing structure but limits upside potential.
FAQs
Q1: What is the primary indication for Zepzelca?
It is used for metastatic small cell lung cancer after failure of initial platinum-based chemotherapy.
Q2: How does Zepzelca’s price compare to similar therapies?
It is priced higher than traditional third-line agents like topotecan, reflecting its novel mechanism and targeting.
Q3: Are there upcoming patent expirations for Zepzelca?
Patents are valid until 2028, delaying generics or biosimilar entry.
Q4: What factors could influence future price reductions?
Increased competition, biosimilar approval, policy caps, and payer negotiations.
Q5: How significant is the market for Zepzelca?
The U.S. market involves approximately 30,000 patients annually, representing a limited but stable niche within the oncology sector.
References
- U.S. Food and Drug Administration (FDA). (2020). Zepzelca (Lurbinectedin) Approval Letter.
- SEER Cancer Statistics. (2023). Lung and bronchus cancer incidence and mortality rates.
- IQVIA. (2023). Pharmaceutical Pricing and Reimbursement Trends.
- FDA Label for Zepzelca. (2020). Indications and Usage.
- Centers for Medicare & Medicaid Services (CMS). (2023). Reimbursement policies for oncology drugs.
